TITLE

Antipsychotic drug warnings indicate need for better communication between endocrinologists, psychiatrists

AUTHOR(S)
Milone, Angelo
PUB. DATE
June 2010
SOURCE
Endocrine Today;Jun2010, Vol. 8 Issue 6, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses the claims of psychiatrists that the series of warnings from the U.S. Food and Drug Administration (FDA) about the adverse effects caused by using second-generation antipsychotic drug suggests a greater need for communication between endocrinologists and psychiatrists in monitoring weight gain, glucose and other lipid levels.
ACCESSION #
50993902

 

Related Articles

  • Antipsychotic drug warnings indicate need for better communication between endocrinologists, psychiatrists. Milone, Angelo // Endocrine Today;Jun2010, Vol. 8 Issue 6, p1 

    The article discusses the claims of psychiatrists that the series of warnings from the U.S. Food and Drug Administration (FDA) about the adverse effects caused by using second-generation antipsychotic drug suggests a greater need for communication between endocrinologists and psychiatrists in...

  • Antipsychotic drug warnings indicate need for better communication between endocrinologists, psychiatrists. Milone, Angelo // Endocrine Today;Jun2010, Vol. 8 Issue 6, p1 

    The article discusses the claims of psychiatrists that the series of warnings from the U.S. Food and Drug Administration (FDA) about the adverse effects caused by using second-generation antipsychotic drug suggests a greater need for communication between endocrinologists and psychiatrists in...

  • US FDA reviews deaths following Zyprexa Relprevv therapy.  // Reactions Weekly;Apr2015, Vol. 1545 Issue 1, p8 

    The article discusses the statement issued by the U.S. Food and Drug Administration on March 23, 2015, concluding the review of the deaths of two patients following treatment with the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate).

  • First Generic Versions of Zyprexa Receive Market Clearance.  // Chain Drug Review;11/21/2011, Vol. 33 Issue 20, p67 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) in 2011 for the marketing of the generic versions of Zyprexa (olanzapine tablets) and Zyprexa Zydus (olanzapine orally disintegrating tablets) for the treatment of schizophrenia and bipolar disorder.

  • FDA Sets Tentative 2010 Advisory Calendar.  // BioWorld Today;1/4/2010, Vol. 21 Issue 1, p6 

    The article announces that the U.S. Food & Drug Administration (FDA) published the 2010 tentative meetings dates for its advisory committees. The dates include nine meetings of the agency's Oncologic Drugs Advisory Committee, as well as five meetings of the Endocrinologic and Metabolic Drugs...

  • New fenofibrate formulation offers more convenience.  // Drug Topics;11/22/2004, Vol. 148 Issue 22, p6 

    Reports that the U.S. Food and Drug Administration has approved a formulation of fenofibrate tablets for the treatment of lipid disorders such as mixed dyslipidemia.

  • Treatments Approved For Two Genetic Disorders.  // RN;Aug2003, Vol. 66 Issue 8, p93 

    Reports on the U.S. Food and Drug Administration's approval of the first treatments for two rare inheritable metabolic disorders, Fabry disease and mucopolysaccharidosis-I (MPS-I). Agalsidase beta for Fabry disease; Laronidase as an enzyme-replacement therapy for MPS-I.

  • ASK TUFTS EXPERTS. Lichtenstein, Alice H. // Tufts University Health & Nutrition Letter;Aug2015, Vol. 33 Issue 6, p8 

    The article presents questions and answers related to nutrition including whether is any safe time span after taking medication to have grapefruit, another asking for what other liquid other than milk may be a substitute for the morning meal and whether raw onions are more nutritious than cooked...

  • Maintenance Treatment Study Designs in Bipolar Disorder Do They Demonstrate that Atypical Neuroleptics (Antipsychotics) are Mood Stabilizers? Goodwin, Frederick K.; Whitham, Elizabeth A.; Ghaeini, S. Nassir // CNS Drugs;2011, Vol. 25 Issue 10, p819 

    In this conceptual review we argue that by certifying some of the atypical neuroleptics (or, if one prefers, antipsychotics) as indicated for the 'maintenance' treatment of bipolar disorder, the US FDA has created confusion in the field. These maintenance indications are based on studies using a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics